Thalassemia News and Research

Latest Thalassemia News and Research

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

New gene transfer technique can treat beta-thalassemia, sickle cell anemia

New gene transfer technique can treat beta-thalassemia, sickle cell anemia

Shire enters agreement to acquire FerroKin BioSciences

Shire enters agreement to acquire FerroKin BioSciences

HemaQuest closes $13 million extension of Series B financing

HemaQuest closes $13 million extension of Series B financing

Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD

Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD

New gene editing technique can heal sickle cell patients with their own cells

New gene editing technique can heal sickle cell patients with their own cells

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Public health officials should address needs of people with blood disorders

Public health officials should address needs of people with blood disorders

FDA licenses NYBC's HEMACORD stem cell product

FDA licenses NYBC's HEMACORD stem cell product

ApoPharma receives FDA approval for Ferriprox to treat transfusional iron overload

ApoPharma receives FDA approval for Ferriprox to treat transfusional iron overload

ODAC recommends ApoPharma's Ferriprox for FDA approval to treat transfusional iron overload

ODAC recommends ApoPharma's Ferriprox for FDA approval to treat transfusional iron overload

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

FDA clears Resonance Health's MRI-Q System for cardiac T2* iron assessment

FDA clears Resonance Health's MRI-Q System for cardiac T2* iron assessment

EGT transfers clinical grade lentiviral vector to MSKCC

EGT transfers clinical grade lentiviral vector to MSKCC

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease

HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease

bluebird bio announces receipt of additional $30 million in financing

bluebird bio announces receipt of additional $30 million in financing

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting